ClariTrial — AI Clinical Trial Intelligence

Explore/autoimmune immunology trials recruiting Phase 2 Phase 3

Status

Phase

39 results for “autoimmune immunology trials recruiting Phase 2 Phase 3”

Page 1 of 3

NCT03323476

Recruiting

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Phase 3Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease

Discontinuation (or not initiation) of Immunosuppressive TherapyMaintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®

Centre Hospitalier Departemental Vendee136 participants58 sites · FranceCompletes Mar 2031

CT.gov Full analysis →

NCT05039840

Recruiting

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Phase 2Systemic Lupus Erythematosus

SAR441344 IVSAR441344 SCPlacebo IV+1 more

Sanofi116 participants74 sites · United States, Argentina, BrazilCompletes Jul 2026

CT.gov Full analysis →

NCT06406205

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

CT.gov Full analysis →

NCT06671483

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

CT.gov Full analysis →

NCT06106906

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT07148791

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT07013110

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

CT.gov Full analysis →

NCT07108387

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jan 2028

CT.gov Full analysis →

NCT07103746

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants9 sites · United StatesCompletes Aug 2028

CT.gov Full analysis →

NCT06106893

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT07284641

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes Feb 2030

CT.gov Full analysis →

NCT04925375

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2026

CT.gov Full analysis →

NCT05398809

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

CT.gov Full analysis →

NCT05201469

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

CT.gov Full analysis →

NCT06189157

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

CT.gov Full analysis →

1–15 of 39

Explore/autoimmune immunology trials recruiting Phase 2 Phase 3

Status

Phase

39 results for “autoimmune immunology trials recruiting Phase 2 Phase 3”

Page 1 of 3

NCT03323476

Recruiting

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Phase 3Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease

Discontinuation (or not initiation) of Immunosuppressive TherapyMaintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®

Centre Hospitalier Departemental Vendee136 participants58 sites · FranceCompletes Mar 2031

CT.gov Full analysis →

NCT05039840

Recruiting

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Phase 2Systemic Lupus Erythematosus

SAR441344 IVSAR441344 SCPlacebo IV+1 more

Sanofi116 participants74 sites · United States, Argentina, BrazilCompletes Jul 2026

CT.gov Full analysis →

NCT06406205

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

CT.gov Full analysis →

NCT06671483

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

CT.gov Full analysis →

NCT06106906

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT07148791

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT07013110

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

CT.gov Full analysis →

NCT07108387

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jan 2028

CT.gov Full analysis →

NCT07103746

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants9 sites · United StatesCompletes Aug 2028

CT.gov Full analysis →

NCT06106893

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT07284641

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes Feb 2030

CT.gov Full analysis →

NCT04925375

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2026

CT.gov Full analysis →

NCT05398809

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

CT.gov Full analysis →

NCT05201469

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

CT.gov Full analysis →

NCT06189157

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

CT.gov Full analysis →

1–15 of 39